We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance

By LabMedica International staff writers
Posted on 16 Jun 2026

Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. More...

Chronological age poorly reflects the physiologic decline that predisposes individuals to cardiovascular, neurodegenerative, renal, pulmonary, and metabolic disease. Clinicians need scalable assays that anticipate risk before symptoms emerge. A new study shows that a blood test estimating the biological ages of 11 organ systems can forecast organ-specific disease and mortality risk years in advance.

Stanford Medicine (Stanford, CA, USA) investigators developed a blood-based algorithm that assigns a biological age to the brain, muscle, heart, lung, arteries, liver, kidneys, pancreas, immune system, intestine, and adipose tissue. Using an advanced commercially available laboratory platform, the team quantified nearly 3,000 plasma proteins, many with organ-restricted origins, and computed age‑adjusted organ-specific protein signatures. The algorithm compared each participant’s signature with population averages to classify organs as “extremely aged” or “extremely youthful” when values deviated by more than 1.5 standard deviations.

The analysis included 44,498 randomly selected adults aged 40 to 70 from the UK Biobank, monitored for up to 17 years. One-third of participants had at least one organ categorized as extremely aged or youthful, and one in four had multiple organs in those extremes. For the brain, each extreme encompassed about 6% to 7% of participants.

Organ-specific biological age was strongly associated with future disease risk. An extremely aged heart predicted a greater likelihood of atrial fibrillation and heart failure, while aged lungs were linked to an increased risk of chronic obstructive pulmonary disease (COPD). Similarly, an aged brain was associated with a markedly higher risk of Alzheimer’s disease.

Compared with a normally aging brain, an extremely aged brain carried a 3.1-fold greater likelihood of developing Alzheimer’s disease, whereas an extremely youthful brain had roughly one-fourth the risk, representing an approximately twelvefold difference in incidence over the following decade. Brain biological age was also the strongest predictor of all-cause mortality: an extremely aged brain increased the risk of death by 182% over approximately 15 years, while an extremely youthful brain reduced it by 40%.

Findings were published online July 9, 2026 in Nature Medicine. A related Nature Medicine paper published June 15, 2026 extended the approach to individual cell types, linking double‑dose APOE4 carriers with “older” astrocytes and showing amyotrophic lateral sclerosis (ALS) incidence was 12.7 times higher among individuals with an aged skeletal‑muscle‑cell profile detectable more than three years before symptom-based diagnosis. The analytical tool is currently available only for research purposes.

“We've developed a blood-based indicator of the age of your organs. With this indicator, we can assess the age of an organ today and predict the odds of your getting a disease associated with that organ 10 years later,” said Tony Wyss-Coray, Ph.D., professor of neurology and neurological sciences and director of the Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute.

“This is, ideally, the future of medicine. Today, you go to the doctor because something aches, and they take a look to see what's broken. We're trying to shift from sick care to health care and intervene before people get organ-specific disease,” added Wyss-Coray.

Related Links
Stanford Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Industry

view channel
Image: The partnership aims to broaden access to ultrasensitive blood-based testing for multiple myeloma and other hematologic malignancies (Image credit: 123RF)

Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies

Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.